FPS
BNTC icon

Fieldpoint Private Securities’s Benitec Biopharma BNTC Stock Holding History

Fieldpoint Private Securities’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1
Closed -$23 – 1501
2022
Q1 		$0 Hold
1
– – ﹤0.01% 1662
2021
Q4 		$0 Hold
1
– – ﹤0.01% 1653
2021
Q3 		$0 Buy
+1
New +$66 ﹤0.01% 1645

Other funds holding BNTC

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fieldpoint Private Securities's BNTC Position: Q2 2022 in Review

Fieldpoint Private Securities sold out of Benitec Biopharma (BNTC) in Q2 2022, closing a stake of 1 share — an estimated $23 sold.

Fieldpoint Private Securities first reported a position in BNTC in Q3 2021 and held it in 3 quarters. The position peaked at $0 in Q1 2022. 21 funds tracked by Wall St. Rank hold BNTC as of Q2 2022.

  • Fieldpoint Private Securities reported no remaining Benitec Biopharma position as of Q2 2022 after selling out during the quarter.
  • Fieldpoint Private Securities sold 1 Benitec Biopharma share in Q2 2022, an estimated $23.
  • Fieldpoint Private Securities first reported a position in Benitec Biopharma in Q3 2021 and held it in 3 quarters.
  • Fieldpoint Private Securities's Benitec Biopharma position peaked at $0 in Q1 2022.
  • 21 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2022.

Based on Fieldpoint Private Securities's 13F filing for Q2 2022, filed 5 Aug 2022.